Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment-1 Study (MISSION-1)
Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment-1 Study (MISSION-1) will evaluate a six-month treatment of a medicine called tofacitinib to see if it can improve the health of individuals with Down syndrome.
Principal investigator
Joaquín Espinosa, PhD
Location
Denver, CO
Age range
6 to 22 years old